Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Castle Biosciences has announced that study results of a proprietary predictive test for esophageal cancer demonstrated strong accuracy and specificity in identifying patients who are likely to have tumors that are extremely resistant to standard pre-surgical treatment of chemotherapy and radiation. Data from this second validation study were presented in San Francisco at the 2014 Gastrointestinal Cancers Symposium sponsored by the American Society of Clinical Oncology.
Medical literature shows that approximately 25% of esophageal cancer patients exhibit extreme resistance to standard regimens of chemotherapy and radiation therapy, and therefore do not respond to the pre-surgical treatment. These patients may avoid the toxicities associated with the treatments and instead can be considered for alternative neoadjuvant therapies or move directly to surgery to remove the tumor.
The test, a three-protein biomarker assay, was discovered by researchers at M.D. Anderson Cancer Center (MDACC). Pre-treatment tumor biopsies are used to evaluate treatment resistance with this predictive assay. Studies show it reliably differentiates patients who are complete or partial responders to chemotherapy and radiation from those who are non-responders. The initial, single center validation study of 167 patients demonstrated an accuracy of 92% and specificity of 97%.
In this second, independent, multi-center study presented today, accuracy was 79% and specificity was 95% for classifying which patients are likely to be highly resistant to pre-surgical chemotherapy treatment for esophageal cancer.
"Locally advanced esophageal cancer can be difficult to treat particularly in patients with comorbid illnesses or advanced age," commented Kenneth Kesler MD, Professor of Surgery, Thoracic Oncology Program, Indiana University. "Induction chemotherapy and radiation therapy are recommended prior to surgery in most cases. However, induction therapy can result in significant toxicity and will achieve no clinical benefits in up to a quarter of patients. The ability to identify resistance to certain chemotherapy agents allows selection of alternative chemotherapy agents or treatment strategies."
The predictive algorithm classifies patients as either exCTRT (extreme resistance to chemo-radiation; College of American Pathology Treatment Response Grade 3) or non-exCTRT (non-extreme resistance to chemo-radiation; College of American Pathology Treatment Response Grade 0, 1, or 2). The test, DecisonDx-EC, uses compartmental localization of the biomarkers NF-kB, Gli1 and SHH in pre-treated tumor biopsies to determine a localization index score for each biomarker. This information is then analyzed using a proprietary algorithm to predict exCTRT or non-exCTRT. The test is currently available for physicians to order through Castle Biosciences. More information can be found at www.myesophagealcancer.com.
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Cancer / Oncology category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Biosciences, Castle. "New biomarker test identifies resistance to chemotherapy and radiation in esophageal cancer patients." Medical News Today. MediLexicon, Intl., 21 Jan. 2014. Web.
8 Mar. 2014. <http://www.medicalnewstoday.com/releases/271444>
Biosciences, C. (2014, January 21). "New biomarker test identifies resistance to chemotherapy and radiation in esophageal cancer patients." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/271444.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.